CLVS

CLVS Articles

Companies receiving analyst upgrades, downgrades, initiations or other key notes on Tuesday morning include Alcoa, Arch Coal, Baidu, Ciena, JD.com and Vale.
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares hit a new 52-week high after the company reported a key U.S. Food and Drug Administration (FDA) approval. Essentially, the FDA approved...
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Netflix, Nike, Pandora Media, SunPower and United Continental.
Clovis Oncology shares saw a massive gain on Tuesday, on the heels of news that the FDA had granted it a priority review of its cancer drug.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Clovis Oncology, Garmin, Lowe's, NetApp, On Deck, Pioneer Natural and RSP Permian.
Clovis Oncology, Inc. (NASDAQ: CLVS) is watching its shares climb late Tuesday after the company announced a key U.S. Food and Drug Administration (FDA) approval. Note that this is the first of a few...
Shares of Clovis Oncology dropped after the FDA Oncologic Drugs Advisory Committee voted against its lung cancer drug.
Although the markets have made their comeback, some stocks are still slowing that recovery and punishing their shareholders. These companies hurt their shareholders last week.
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Clovis Oncology, CSC, Norfolk Southern, Sprint, Square and Western Digital.
April 12, 2016: Here are four stocks trading with relatively heavy volume among 17 equities making new 52-week lows in Tuesday’s session. The day’s NYSE winners led losers by about 3 to 1. Nasdaq...
April 11, 2016: Here are four stocks trading with relatively heavy volume among 21 equities making new 52-week lows in Monday’s session. The day’s NYSE winners led losers by about 3-to-2. Nasdaq...
Thursday's top analyst calls include General Electric, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell.
This is going to be a big year in biotech, with a host of drugs set to undergo FDA scrutiny. These four companies with promising candidates all have dates with the agency this year.
Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk...
24/7 Wall St. examines Valeant Pharmaceuticals and other biotech stocks with incredible gains or losses over the course of the past week.